Rita C. Peters

The mission continues. Let science be the guide.

Congress questions FDA on plans to catch up and move forward with facility inspections as pandemic travel restrictions ease.

Vaccines define the path to putting pandemic restrictions and pain in the rear-view mirror.

Bio/pharmaceutical manufacturers have made a good first step toward global vaccination through pledging doses at no- to low-profit rates.

As face masks start to come off, bio/pharma’s COVID-19 battle goes on.

Smart, accurate, science-based messaging is needed to advance bio/pharma science.

Bio/pharma works hard today to change the calendar to tomorrow.

A complicated vaccination rollout and mixed messages may derail the pandemic endgame

Demand for specific advanced laboratory skills creates a positive employment market.

After a hectic 2020, biopharma looks to deliver on COVID-19 vaccines and move other promising therapies forward.

Essential bio/pharma employees show hard work and dedication can pay off, for patients.

Shutting down the COVID-19 pandemic requires a global, selfless effort.

After a difficult year, biopharma science delivers promising results.

Resolving drug shortages starts with identifying the source of the problem.

Misleading messages contribute to eroding trust in public health agencies

Amid high expectations for a COVID-19 vaccine, biopharma readies production capacity, weighs external pressures.

Time sure flies, except when you are waiting for something to happen.

Data and science must guide FDA in making pressure-filled COVID-19 vaccine and therapy approval decisions.

Achieving herd immunity will require testing, data, a vaccine, and public support.

Will moving at “warp speed” to develop a vaccine impact efficacy or safety?

With some FDA inspections on hold, will the US drug supply maintain its quality standards?

Contract service organizations can offer biopharma companies early insight into dangers that may hinder a drug’s later development.

Technology and capacity investments create opportunities in the cell and gene therapy arena for CDMOs and biopharma alike.

Bio/pharma researchers mobilize to diagnose and treat patients in pandemic threat.

Achieving effective manufacturing processes and sufficient capacity remains a top priority across a diversified biologic drug pipeline.

The promise of new therapies is tempered by the need for affordability, safety, and ethics.

With a positive employment market, some biopharma professionals explore options for career advancement.

Warning letters tell the tale of missteps by drug companies and offer a path to compliance for quality teams that monitor these enforcement actions.

Nearly four decades after the first diagnosis, the fight to treat HIV/AIDs continues.

FDA report says drug shortages are underappreciated and patients pay a price.